![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CPSF2 |
Gene summary for CPSF2 |
![]() |
Gene information | Species | Human | Gene symbol | CPSF2 | Gene ID | 53981 |
Gene name | cleavage and polyadenylation specific factor 2 | |
Gene Alias | CPSF100 | |
Cytomap | 14q32.12 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | A0A024R6H0 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
53981 | CPSF2 | LZE4T | Human | Esophagus | ESCC | 6.05e-11 | 3.71e-01 | 0.0811 |
53981 | CPSF2 | LZE5T | Human | Esophagus | ESCC | 1.93e-06 | 4.94e-01 | 0.0514 |
53981 | CPSF2 | LZE7T | Human | Esophagus | ESCC | 2.86e-06 | 2.22e-01 | 0.0667 |
53981 | CPSF2 | LZE20T | Human | Esophagus | ESCC | 9.91e-06 | 2.27e-01 | 0.0662 |
53981 | CPSF2 | LZE24T | Human | Esophagus | ESCC | 2.41e-20 | 3.65e-01 | 0.0596 |
53981 | CPSF2 | LZE6T | Human | Esophagus | ESCC | 1.47e-02 | 2.06e-01 | 0.0845 |
53981 | CPSF2 | P1T-E | Human | Esophagus | ESCC | 7.02e-03 | 1.59e-01 | 0.0875 |
53981 | CPSF2 | P2T-E | Human | Esophagus | ESCC | 5.02e-24 | 3.81e-01 | 0.1177 |
53981 | CPSF2 | P4T-E | Human | Esophagus | ESCC | 1.48e-27 | 6.14e-01 | 0.1323 |
53981 | CPSF2 | P5T-E | Human | Esophagus | ESCC | 1.11e-19 | 3.56e-01 | 0.1327 |
53981 | CPSF2 | P8T-E | Human | Esophagus | ESCC | 1.05e-14 | 2.84e-01 | 0.0889 |
53981 | CPSF2 | P9T-E | Human | Esophagus | ESCC | 9.71e-10 | 2.21e-01 | 0.1131 |
53981 | CPSF2 | P10T-E | Human | Esophagus | ESCC | 7.19e-22 | 4.26e-01 | 0.116 |
53981 | CPSF2 | P11T-E | Human | Esophagus | ESCC | 3.34e-06 | 3.18e-01 | 0.1426 |
53981 | CPSF2 | P12T-E | Human | Esophagus | ESCC | 1.24e-25 | 5.13e-01 | 0.1122 |
53981 | CPSF2 | P15T-E | Human | Esophagus | ESCC | 1.22e-25 | 5.43e-01 | 0.1149 |
53981 | CPSF2 | P16T-E | Human | Esophagus | ESCC | 5.01e-22 | 3.40e-01 | 0.1153 |
53981 | CPSF2 | P17T-E | Human | Esophagus | ESCC | 2.65e-07 | 3.14e-01 | 0.1278 |
53981 | CPSF2 | P19T-E | Human | Esophagus | ESCC | 3.83e-05 | 3.90e-01 | 0.1662 |
53981 | CPSF2 | P20T-E | Human | Esophagus | ESCC | 3.01e-12 | 2.46e-01 | 0.1124 |
Page: 1 2 3 4 5 6 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Cervix | N_HPV | ![]() |
Endometrium | AEH | ![]() |
Endometrium | EEC | ![]() |
Prostate | BPH | ![]() |
Prostate | Tumor | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00905013 | Esophagus | ESCC | RNA phosphodiester bond hydrolysis | 110/8552 | 152/18723 | 1.95e-11 | 6.81e-10 | 110 |
GO:00903053 | Esophagus | ESCC | nucleic acid phosphodiester bond hydrolysis | 163/8552 | 261/18723 | 3.07e-08 | 5.73e-07 | 163 |
GO:003112412 | Esophagus | ESCC | mRNA 3'-end processing | 47/8552 | 62/18723 | 1.29e-06 | 1.58e-05 | 47 |
GO:00311233 | Esophagus | ESCC | RNA 3'-end processing | 76/8552 | 116/18723 | 1.25e-05 | 1.15e-04 | 76 |
GO:00063783 | Esophagus | ESCC | mRNA polyadenylation | 33/8552 | 44/18723 | 7.30e-05 | 5.49e-04 | 33 |
GO:00436313 | Esophagus | ESCC | RNA polyadenylation | 33/8552 | 45/18723 | 1.54e-04 | 1.02e-03 | 33 |
GO:00063793 | Esophagus | ESCC | mRNA cleavage | 17/8552 | 22/18723 | 2.60e-03 | 1.11e-02 | 17 |
GO:00987872 | Esophagus | ESCC | mRNA cleavage involved in mRNA processing | 11/8552 | 14/18723 | 1.30e-02 | 4.27e-02 | 11 |
GO:00311241 | Liver | HCC | mRNA 3'-end processing | 50/7958 | 62/18723 | 8.44e-10 | 2.60e-08 | 50 |
GO:00905011 | Liver | HCC | RNA phosphodiester bond hydrolysis | 101/7958 | 152/18723 | 1.99e-09 | 5.63e-08 | 101 |
GO:00311231 | Liver | HCC | RNA 3'-end processing | 81/7958 | 116/18723 | 2.27e-09 | 6.32e-08 | 81 |
GO:0090305 | Liver | HCC | nucleic acid phosphodiester bond hydrolysis | 152/7958 | 261/18723 | 1.90e-07 | 3.46e-06 | 152 |
GO:0006378 | Liver | HCC | mRNA polyadenylation | 35/7958 | 44/18723 | 5.70e-07 | 9.03e-06 | 35 |
GO:0043631 | Liver | HCC | RNA polyadenylation | 35/7958 | 45/18723 | 1.51e-06 | 2.15e-05 | 35 |
GO:0006379 | Liver | HCC | mRNA cleavage | 17/7958 | 22/18723 | 9.84e-04 | 5.70e-03 | 17 |
GO:0098789 | Liver | HCC | pre-mRNA cleavage required for polyadenylation | 11/7958 | 13/18723 | 2.38e-03 | 1.16e-02 | 11 |
GO:0008334 | Liver | HCC | histone mRNA metabolic process | 13/7958 | 17/18723 | 4.77e-03 | 2.02e-02 | 13 |
GO:0098787 | Liver | HCC | mRNA cleavage involved in mRNA processing | 11/7958 | 14/18723 | 6.81e-03 | 2.73e-02 | 11 |
GO:00311242 | Oral cavity | OSCC | mRNA 3'-end processing | 49/7305 | 62/18723 | 1.40e-10 | 4.14e-09 | 49 |
GO:00905012 | Oral cavity | OSCC | RNA phosphodiester bond hydrolysis | 95/7305 | 152/18723 | 3.65e-09 | 8.22e-08 | 95 |
Page: 1 2 3 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0301524 | Esophagus | ESCC | mRNA surveillance pathway | 72/4205 | 97/8465 | 6.12e-07 | 4.10e-06 | 2.10e-06 | 72 |
hsa0301534 | Esophagus | ESCC | mRNA surveillance pathway | 72/4205 | 97/8465 | 6.12e-07 | 4.10e-06 | 2.10e-06 | 72 |
hsa0301521 | Liver | HCC | mRNA surveillance pathway | 66/4020 | 97/8465 | 3.16e-05 | 1.88e-04 | 1.04e-04 | 66 |
hsa0301531 | Liver | HCC | mRNA surveillance pathway | 66/4020 | 97/8465 | 3.16e-05 | 1.88e-04 | 1.04e-04 | 66 |
hsa030158 | Oral cavity | OSCC | mRNA surveillance pathway | 75/3704 | 97/8465 | 1.30e-11 | 2.01e-10 | 1.02e-10 | 75 |
hsa0301513 | Oral cavity | OSCC | mRNA surveillance pathway | 75/3704 | 97/8465 | 1.30e-11 | 2.01e-10 | 1.02e-10 | 75 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CPSF2 | SNV | Missense_Mutation | novel | c.632N>A | p.Arg211Lys | p.R211K | Q9P2I0 | protein_coding | tolerated(0.15) | benign(0.241) | TCGA-A2-A04W-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
CPSF2 | SNV | Missense_Mutation | novel | c.245G>T | p.Cys82Phe | p.C82F | Q9P2I0 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-AR-A24S-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD |
CPSF2 | SNV | Missense_Mutation | novel | c.839N>T | p.Ser280Phe | p.S280F | Q9P2I0 | protein_coding | deleterious(0) | possibly_damaging(0.803) | TCGA-BH-A2L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
CPSF2 | SNV | Missense_Mutation | c.794N>T | p.Ser265Leu | p.S265L | Q9P2I0 | protein_coding | deleterious(0.01) | possibly_damaging(0.456) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
CPSF2 | SNV | Missense_Mutation | rs759034098 | c.1298C>T | p.Ser433Leu | p.S433L | Q9P2I0 | protein_coding | tolerated(0.35) | benign(0.007) | TCGA-EX-A1H6-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
CPSF2 | SNV | Missense_Mutation | novel | c.15C>G | p.Ile5Met | p.I5M | Q9P2I0 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-VS-A8QC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | paclitaxel | PD |
CPSF2 | SNV | Missense_Mutation | novel | c.1270N>A | p.Asp424Asn | p.D424N | Q9P2I0 | protein_coding | tolerated(0.15) | benign(0.236) | TCGA-VS-A9UQ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
CPSF2 | SNV | Missense_Mutation | c.917N>A | p.Arg306His | p.R306H | Q9P2I0 | protein_coding | deleterious(0) | probably_damaging(0.96) | TCGA-A6-6654-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | oxaliplatin | SD | |
CPSF2 | SNV | Missense_Mutation | c.1508N>T | p.Gly503Val | p.G503V | Q9P2I0 | protein_coding | tolerated(0.33) | benign(0.001) | TCGA-AA-3502-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
CPSF2 | SNV | Missense_Mutation | c.137N>C | p.Asp46Ala | p.D46A | Q9P2I0 | protein_coding | deleterious(0.05) | benign(0.407) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |